BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33283580)

  • 1. Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience.
    Assi R; Kantarjian H; Keating M; Pemmaraju N; Verstovsek S; Garcia-Manero G; Ravandi F; Borthakur G; Dahl J; Jabbour E; Cortes JE
    Leuk Lymphoma; 2021 Apr; 62(4):909-917. PubMed ID: 33283580
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fertility and pregnancy in chronic myeloid leukemia: real-world experience from an Indian tertiary care institution.
    R C; Malik PS; Sahoo RK; Sharawat S; Singh M; Garg V; Bhatia K; Kantak A; Kumar S; Kumar L
    Ann Hematol; 2023 Aug; 102(8):2087-2096. PubMed ID: 37322094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Planned Pregnancy in Female Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy.
    Dou X; Qin Y; Huang X; Jiang Q
    Oncologist; 2019 Nov; 24(11):e1141-e1147. PubMed ID: 31186377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of stopping tyrosine kinase inhibitors during pregnancy on disease status and reproductive outcomes among patients with chronic myeloid leukemia].
    Zhao HF; Zhang Y; Li Z; Zhou J; Zu YL; Yu FK; Gui RR; Wei XD; Song YP
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jul; 39(7):540-545. PubMed ID: 30122011
    [No Abstract]   [Full Text] [Related]  

  • 5. Pregnancy outcomes of women whom spouse fathered children after tyrosine kinase inhibitor therapy for chronic myeloid leukemia: A systematic review.
    Szakács Z; Hegyi PJ; Farkas N; Hegyi P; Balaskó M; Erős A; Szujó S; Pammer J; Mosdósi B; Simon M; Nagy A; Für G; Hussain A
    PLoS One; 2020; 15(12):e0243045. PubMed ID: 33270732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Fertility and disease outcomes in patients with chronic myeloid leukemia].
    Dou XL; Qin YZ; Shi HX; Lai YY; Hou Y; Huang XJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2019 Dec; 40(12):980-985. PubMed ID: 32023726
    [No Abstract]   [Full Text] [Related]  

  • 7. Pregnancies in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitor.
    Zhou L; You JH; Wu W; Li JM; Shen ZX; Wang AH
    Leuk Res; 2013 Oct; 37(10):1216-21. PubMed ID: 23937984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical analysis about the management and the perinatal outcomes of pregnancy with chronic myeloid leukemia].
    Wang DP; Liang MY; Zhang XH; Wang SM
    Zhonghua Fu Chan Ke Za Zhi; 2010 Oct; 45(10):735-9. PubMed ID: 21176552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pregnancy and long-term outcomes of female patients with chronic myeloid leukemia on tyrosine kinase inhibitors who experienced unplanned pregnancies.
    Bhattacharjee U; Jandial A; Singh C; Lekshmon KS; Mishra K; Sandal R; Nampoothiri R; Naseem S; Suri V; Jain A; Lad DP; Prakash G; Khadwal A; Malhotra P
    Leuk Res; 2023 Oct; 133():107367. PubMed ID: 37566974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
    Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
    Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia.
    Lasica M; Willcox A; Burbury K; Ross DM; Branford S; Butler J; Filshie R; Januszewicz H; Joske D; Mills A; Simpson D; Tam C; Taylor K; Watson AM; Wolf M; Grigg A
    Leuk Lymphoma; 2019 Jul; 60(7):1796-1802. PubMed ID: 30632843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discontinuation of tyrosine kinase inhibitors in pediatric chronic myeloid leukemia.
    Shima H; Kada A; Tanizawa A; Sato I; Tono C; Ito M; Yuza Y; Watanabe A; Kamibeppu K; Uryu H; Koh K; Imai C; Yoshida N; Koga Y; Fujita N; Saito AM; Adachi S; Ishii E; Shimada H
    Pediatr Blood Cancer; 2022 Aug; 69(8):e29699. PubMed ID: 35403816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pregnancy Outcomes in Chronic Myeloid Leukemia: A Single Center Experience.
    Madabhavi I; Sarkar M; Modi M; Kadakol N
    J Glob Oncol; 2019 Sep; 5():1-11. PubMed ID: 31584851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pregnancy among patients with chronic myeloid leukemia treated with imatinib.
    Ault P; Kantarjian H; O'Brien S; Faderl S; Beran M; Rios MB; Koller C; Giles F; Keating M; Talpaz M; Cortes J
    J Clin Oncol; 2006 Mar; 24(7):1204-8. PubMed ID: 16446320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Family Planning and Pregnancy in Patients with Chronic Myeloid Leukemia.
    Berman E
    Curr Hematol Malig Rep; 2023 Apr; 18(2):33-39. PubMed ID: 36763239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fertility considerations in targeted biologic therapy with tyrosine kinase inhibitors: a review.
    Rambhatla A; Strug MR; De Paredes JG; Cordoba Munoz MI; Thakur M
    J Assist Reprod Genet; 2021 Aug; 38(8):1897-1908. PubMed ID: 33826052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic myeloid leukemia (CML) in children and adolescents-Clinicopathological findings.
    Nevejan L; Labarque V; Boeckx N
    Eur J Haematol; 2024 Mar; 112(3):458-465. PubMed ID: 37985225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Features and Treatment Outcomes of 51 Patients with Chronic Myeloid Leukemia Treated with a Tyrosine Kinase Inhibitor at a Single Institution from 2002 to 2014.
    Kawano N; Yoshida S; Kawano S; Kuriyama T; Yamashita K; Ochiai H; Shimoda K; Ishikawa F; Ueda A; Kikuchi I
    J Clin Exp Hematop; 2016; 56(1):34-42. PubMed ID: 27334856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
    Saussele S; Richter J; Guilhot J; Gruber FX; Hjorth-Hansen H; Almeida A; Janssen JJWM; Mayer J; Koskenvesa P; Panayiotidis P; Olsson-Strömberg U; Martinez-Lopez J; Rousselot P; Vestergaard H; Ehrencrona H; Kairisto V; Machová Poláková K; Müller MC; Mustjoki S; Berger MG; Fabarius A; Hofmann WK; Hochhaus A; Pfirrmann M; Mahon FX;
    Lancet Oncol; 2018 Jun; 19(6):747-757. PubMed ID: 29735299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.